Sanders calls on USPTO to block Gilead patent extension

US presidential candidate Bernie Sanders has called on the US Patent and Trademark Office (USPTO) to block extensions to two Gilead Sciences patents covering HIV prevention drugs including Descovy (tenofovir alafenamide/embicitrane).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Senators demand USPTO probe into Gilead allegations

16 December 2019 The US Patent and Trademark Office is coming under increasing pressure to review allegations that Gilead delayed development of its latest HIV drug in order to maximise profits.

Americas

US government sues Gilead for patent infringement over HIV drugs

7 November 2019 The US government is suing Gilead for patent infringement, claiming that the pharmaceutical company has been piggybacking on public research to earn billions from its HIV drugs.

Americas

Gilead challenges US govt patents on HIV drug Truvada

22 August 2019 Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Sanders calls on USPTO to block Gilead patent extension

More on this story

Editor's picks

Editor's picks

More features